datopotamab deruxtecan + capecitabine + bevacizumab

This is a **combination regimen** of three pharmaceuticals used or studied in the treatment of advanced cancers, especially breast cancer and non-small cell lung cancer. - **Datopotamab deruxtecan** is a Trop-2-directed antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody linked via a tetrapeptide-based cleavable linker to a potent topoisomerase I inhibitor (deruxtecan). It selectively binds to Trop-2 on cancer cells, is internalized, and releases its payload to induce DNA damage and apoptosis[1][2][3][4][5]. - **Capecitabine** is an oral small molecule prodrug of 5-fluorouracil, a chemotherapeutic antimetabolite that is converted in vivo to cytotoxic 5-FU, inhibiting thymidylate synthase and impairing DNA synthesis. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), preventing binding to its receptor and inhibiting angiogenesis, which restricts tumor blood supply and growth. The regimen is primarily studied in solid tumors, particularly metastatic breast cancer and EGFR-mutated non-small cell lung cancer, often in patients who have progressed after prior therapies.

Other names

datopotamab deruxtecan + capecitabine + bevacizumab